Accessibility Menu
Pyxis Oncology logo

Pyxis Oncology(NASDAQ) PYXS

Market Cap$260.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-74%
5 YearN/A
1 Year+169%
1 Month+40%
Premium Feature
Moneyball Superscore
41/100
$3.13
+0.32%
+0.01Today
Pyxis Oncology last closing stock price
MetricPriceDate
Last closeUSD 3.122026-08-20
Pyxis Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.65%USD 3.012026-08-13
1 month+39.91%USD 2.232026-07-21
3 month+59.18%USD 1.962026-05-22
Year to date+171.3%USD 1.152025-12-31
1 year+168.97%USD 1.162025-08-20
3 year+43.78%USD 2.172023-08-21
Since inception-74.47%USD 13.202021-10-08

Pyxis Oncology Financials at a Glance

Market Cap

$260.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.04M

Net Income (TTM)

-$88.73M

EPS (TTM)

-$1.40

P/E Ratio

-2.22

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$3.13

Volume

253,829.011

Open

$3.15

Previous Close

$3.12

Daily Range

$3.02 - $3.21

52-Week Range

$1.03 - $5.55

Estimated Earnings Date

Nov 2, 2026

PYXS News

No articles available.

PYXS: Motley Fool Moneyball Superscore

41

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pyxis Oncology

Pyxis Oncology, Inc. makes experimental medicines to treat hard-to-cure cancers. These drugs find specific proteins in tumors to deliver medicine directly to them. This helps patients with solid tumors who have few other treatment options.

The Targeted Therapy Toolkit

  • Antibody-Drug Conjugates: Experimental treatments that use a guided approach to kill cancer cells while sparing healthy tissue; includes the lead candidate MICVO.
  • Combination Therapies: Research programs testing MICVO with other approved immune-system drugs to enhance the attack on advanced tumors.
  • Immuno-Oncology Pipeline: Early-stage drug candidates designed to stop cancer from hiding from the body's natural immune response.

Progress in the Lab

  • Announced a clinical trial collaboration with Merck in Nov. 2024 to test MICVO alongside the immune therapy pembrolizumab.
  • Started a dose expansion phase for its lead drug in Jan. 2025 to test efficacy in specific head and neck cancers.
  • Modified its clinical dosing strategy in Dec. 2025 by adding a dose cap to improve patient safety and tolerability.
  • Presented preclinical data at a major medical meeting in April 2026 showing potential synergistic effects with other cancer drugs.

A Specialized Scientific Strategy

Pyxis targets a protein found in many solid tumors but rarely in healthy adult tissue. This approach uses a three-way method to kill cancer cells directly, trigger an immune response, and destroy nearby tumor cells.

Tracking the Financials

  • Net loss was $48.6 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable debt securities totaled $33.0 million as of June 30, 2026.
  • Research and development expenses rose to $36.0 million for the first half of 2026.
  • Completed a private placement financing in July 2026 that generated gross proceeds of approximately $50 million.

Bottom Line

Pyxis has evolved from a preclinical startup to a clinical-stage firm focused on targeted cancer delivery. The company continues to refine its drug dosing and combination strategies to address unmet needs in advanced oncology.

AI Generated • Aug 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

56

CEO

Thomas Civik, MBA

Website

www.pyxisoncology.com

Headquarters

Boston, MA 02118, US

PYXS Financials

Key Financial Metrics (TTM)

Gross Margin

99.76%

Operating Margin

-834.44%

Net Income Margin

-803.83%

Return on Equity

-215.23%

Return on Capital

-117.12%

Return on Assets

-161.55%

Earnings Yield

-45.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$260.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

83.41M

Volume

253.83K

Avg. Volume

1.20M

Financials (TTM)

Gross Profit

$11.01M

Operating Income

-$92.11M

EBITDA

-$83.44M

Operating Cash Flow

-$67.91M

Capital Expenditure

-$9.00K

Free Cash Flow

-$67.92M

Cash & ST Invst.

$33.00M

Total Debt

$17.83M

Pyxis Oncology Performance Analysis

Pyxis Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 16,146,000N/A
20252025-12-31USD 13,858,000-14.2%
Pyxis Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31-100.0%
Q22026-06-30N/A
Pyxis Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.6555.0%
20232023-12-31USD -1.85-49.4%
20242024-12-31USD -1.32-28.5%
20252025-12-31USD -1.28-3.2%
Pyxis Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-16.7%
Q42025-12-3117.1%
Q12026-03-31-27.6%
Q22026-06-30-8.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$260.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.65M

N/A

Employees

56

N/A

Net Income

-$25.35M

-38.1%

EBITDA

-$25.05M

-42.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$33.00M

-62.9%

Total Debt

$17.83M

-8.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$16.01M

-10.5%

Short Term Debt

$1.82M

+16.3%

Return on Assets

-1.62%

N/A

Return on Invested Capital

-3.36%

N/A

Free Cash Flow

-$18.21M

-5.5%

Operating Cash Flow

-$18.21M

-5.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYGRVoyager Therapeutics, Inc.
$3.31-0.45%
IMRXImmuneering Corporation
$5.36+2.00%
CRBUCaribou Biosciences, Inc.
$1.67+3.42%
TNYATenaya Therapeutics, Inc.
$0.71+2.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.67+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.42+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.71+0.09%
MARAMara Holdings
$11.18+0.00%

Questions About PYXS

What is the current price of Pyxis Oncology?

Pyxis Oncology is trading at $3.18 per share.

What is the 52-week range for Pyxis Oncology?

Over the past 52 weeks, Pyxis Oncology has traded between $1.03 and $5.55.

How much debt does Pyxis Oncology have?

As of the most recent reporting period, Pyxis Oncology reported total debt of $17.83M.

How much cash does Pyxis Oncology have on hand?

Pyxis Oncology reported $20.33M in cash and cash equivalents in its most recent financial results.

What is Pyxis Oncology’s dividend yield?

Pyxis Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services